Global /China /Healthcare /Biotechnology /1548
chevron_leftBack
Genscript Biotech Corp. logo

Genscript Biotech Corp.

1548
SHEK: 1548 Delayed
13.72HKD 0.7%
1.75 USD
As of 13 June 2026, Genscript Biotech Corp. has a market cap of $3.8B USD, ranking #4612 globally and #946 in China. It ranks #352 in the Healthcare sector, and #63 in the Biotechnology industry.
Global Rank
4612
Country Rank
946
Sector Rank
352
Industry Rank
63
Key Stats
Market Cap
$3.8BUSD
29.8B HKD
Enterprise Value
$3.34BUSD
26.2B HKD
Revenue (TTM)
$952.94MUSD
7.47B HKD
EBITDA (TTM)
$315.43MUSD
2.47B HKD
Net Income (TTM)
-$529.17MUSD
-4.15B HKD
EBITDA Margin
33%
Profit Margin
-56%
Forward PE
43.7
PS Ratio
4.0
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Weihui Shao open_in_new
Employees
6,165
Founded
2002
Website
genscript.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.7% -1.5% 23% 6.5% -15% 25%

News

Loading...

Markets

Exchange Ticker Price
Hong Kong Stock Exchange
MIC: XHKG
PRIMARY
1548
Genscript Biotech Corp Class H
ISIN: KYG3825B1059
Shares Out.:
2.165B1 Shares Float: 1.121B2
TV:
SA:
YF:
GF:
BA:
MS:
13.72 HKD
OTC Markets
MIC: OTCM
GNNSF
Genscript Biotech Corp Class H
ISIN: KYG3825B1059
Shares Out.:
2.154B1 Shares Float: 1.106B2
TV:
SA:
YF:
GF:
BA:
MS:
2.19 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Genscript Biotech Corp.

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.

Similar Companies

Industry: Biotechnology (China)
Name
Market Cap diff.
PE
$17.44B
136.71B HKD
359%
25.3
$12.2B
95.58B HKD
221%
22.1
$8.0B
54.23B CNY
110%
34.4
$7.33B
49.69B CNY
93%
-
1530
$7.08B
55.5B HKD
86%
5.8
$6.72B
45.52B CNY
77%
61.6
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
5K%
23.9
GILD
$159.92B
4K%
19.0
ARGX
$47.84B
41.39B EUR
1K%
39.9
$44.84B
68.19T KRW
1K%
35.5
CSL
$42.36B
60.27B AUD
1K%
29.3
LONN
$42.3B
33.71B CHF
1K%
37.2
chevron_leftBack